Case Report

**Trigeminal Neuralgia: Report of a Case and Literature Review**

Sadat SMA¹, Sultana A², Rita SN², Khan MR³

**Abstract**

Trigeminal neuralgia is a sudden, severe, stabbing, recurrent and usually unilateral pain in the distribution of one or more branches of the fifth cranial nerve. A 55 years old man, diagnosed case of Trigeminal Neuralgia of the left side of the face was treated with oral carbamazepine with good response. But after that the disease became refractory to the drug. With the titration of dose of carbamazepine, raising up to 1200 mg daily in three equal divided doses added with amitriptylne, we could give relief of pain to patient. The patient is now under observation & we are following him for last 6 months with a good response of the combination drug. It justifies that alteration, titration of carbamazepine and combination with amitriptylne can cause remission of trigeminal neuralgia instead of doing surgical intervention.

**Keywords:** Carbamazepine, Trigeminal Neuralgia

**Introduction**

Trigeminal neuralgia is a sudden, severe, stabbing, recurrent and usually unilateral pain in the distribution of one or more branches of the fifth cranial nerve. Some patients may have a background dull aching pain after the main attack. It is seen more in women than men and affects usually between the fifth and eighth decade of life¹. Trigeminal Neuralgia occurs more frequently in the second and third divisions of the trigeminal nerve. It is also characterized by regions of increased arousal, called trigger zones. The attack is sometimes associated with salivation, lacrimation, rhinorrhea, nasal mucosa congestion and skin redness.

In trigeminal neuralgia, the myelin sheath around the nerves disappear over time due to degenerative processes of aging and vascular compression acting for years about the root of the trigeminal nerve². TN may also be related to incorrect surgery of oral and maxillofacial trauma³. Proper history with meticulous clinical examination with imaging studies is necessary to exclude other causes of facial pain and thus diagnosis of trigeminal neuralgia. Nurmikko and Eldridge proposed three types of trigeminal neuralgia: typical, atypical and trigeminal neuropathy⁴. A distinction is made between classical trigeminal neuralgia where the etiology is unknown or due to vascular compression as compared with symptomatic trigeminal neuralgia was the trigeminal neuralgia is secondary to a tumor, MS or a structural abnormality of the skull base.

TN is treated by both conservative and surgical approaches⁵. Medical therapy is usually considered first and functional neurosurgery is done only in case where clinical therapy proves ineffective⁶. Drug treatment is the use of anticonvulsants, centrally acting muscle relaxants, neuroleptics and local anesthetics. Surgical treatment aims to interruption of peripheral trigeminal pathways or the elimination of possible causes⁷.

Many trials of treatment for trigeminal neuralgia do not state the diagnostic criteria used, do not have robust outcome measures and so may account for the variations in results. There are relatively few large high quality randomized controlled trials of medical management in trigeminal neuralgia and their design is so variable that meta-analysis is virtually impossible. There is, therefore, a need for some future guidelines for the conduct of randomized controlled trials (RCT) in trigeminal neuralgia. The aim of this study was to present a case of trigeminal neuralgia which responded well with conservative approach though initially was refractory. The review provides some evidence based guidance on medical management of trigeminal neuralgia and also to put forward some recommendations of how to design trials in the future.

**Case Report**

A 55 years old man, hailing from Bogura, with diagnosed case of Trigeminal Neuralgia of the left side of the face, reported to the department of Oral & Maxillofacial Surgery, Dhaka Dental College Hospital on September 2013. Patient had been getting treatment of the classic form of the disease with conventional medications (Tegretol 200mg twice daily) by a local doctor for the last 11 years. The patient’s initial complain was pain on the left side of the lower face which was sharp, shooting, lancinating type started mainly during taking food or washing face. Initially the pain lasted for few seconds with gradually increasing in duration & frequency of attack. Then he was treated with oral carbamazepine with an initial divided dose of 200 mg daily which was gradually increased to 600mg in three divided doses within 6 months period. With good response to the prescribed medications patient was well for two years. The initial response to the drug was good but caused weakness, drowsiness, dizziness and so patient himself used to discontinue the medication occasionally. After two years, pain reappeared with non-responsiveness of the drug. The frequency of pain increased and gradually distributed to mid face and upper face with three years period. Then the attending physician increased the dose up to 800mg/day in three divided doses with a combination

---

1. Corresponding Author: Dr. S. M. Anwar Sadat
   BDS, BCS, MCPS, FCPS, MS (OMS), Resident Surgeon
   Department of Oral & Maxillofacial Surgery
   Dhaka Dental College Hospital, Dhaka
   e-mail: an_sadat@yahoo.com

2. Dr. Afia Sultana, BDS, PGT (Oral Surgery)
   Honorary Medical Officer
   Department of Oral & Maxillofacial Surgery
   Dhaka Dental College Hospital, Dhaka

3. Dr. Sufia Nasrin Rita, BDS, FCPS (Orthodontics)
   Associate Professor & Head
   Department of Orthodontics
   Sapporo Dental College Hospital

4. Dr. Md. Raziiuddin Khan, BDS, DDS
   Associate Professor. Department of Anatomy
   Dhaka Dental College, Dhaka
of vitamin B12 & vitamin B6. The drug worked for 7 more years with adjustment of doses at a regular interval. But after that the disease became refractory to Tegretol. The patient then took Gabapentin for another 2 years with the dose of 300mg twice daily which also failed to give remission to the patient. Then patient came to our hospital for better treatment. Hematological profiles and liver function tests were normal. Orthopantomogram and paranasal view radiograph were done to exclude other possibilities of pain. Magnetic Resonance Imaging or Magnetic Resonance Angiogram could not be done due to financial constraint though these were necessary to identify any intra cranial causes of trigeminal neuralgia. Considering patient’s age, body built, physical condition, we again started carbamazepine with initial dose of 600mg/day along with an anti-depressant drug (amitriptylene 10mg once daily) instead of surgical intervention. With the titration of doses raising up to 1200 mg daily in three equal divided doses we could give relief of pain to patient. The patient is now under observation & we are following him for last 6 months with a good response with carbamazepine and amitryptylene in above mentioned doses. It justifies that alteration, titration of carbamazepine and combination with amitryptylene can cause remission of trigeminal neuralgia instead of doing surgical intervention.

Discussion

Diagnosis of Trigeminal Neuralgia is mostly by history and clinical findings. It presents with sudden and severe lancinating pain usually lasts few seconds to minutes, within the distribution of trigeminal nerve, mostly the mandibular or maxillary branches. Pain is often evoked by trivial stimulation in the “trigger zones.”

Sometimes the pain is so severe and aggravated by talking, drinking, eating, tooth brushing or face washing. The nerves affected are usually stereotyped for a particular patient and lie within the sensory distribution of the trigeminal nerve.

Diagnostic criteria for classic trigeminal neuralgia

• Sudden and severe lancinating pain which is aroxysmal in nature
• Pain lasts fraction of a second to minutes that affect one or more divisions of the trigeminal nerve
• Pain has at least one of the following characteristics intense, sharp, superficial, or stabbing precipitated from trigger areas or by trigger factors
• Attacks are similar in individual patients
• No neurological deficit is clinically evident
• Not attributed to another disorder

Sometimes pain of trigeminal neuralgia does not fit the usual criteria exactly because of a persistent ache between paroxysms or mild sensory loss. Such disease is known as “atypical”9 or “mixed” trigeminal neuralgia9. Patients with atypical disease are more likely to have symptomatic rather than idiopathic disease, and they are often more refractory to treatment9 than those with classic trigeminal neuralgia10. Atypical trigeminal neuralgia should not be confused with atypical facial pain (table 1). Other causes of facial pain are much more common than trigeminal neuralgia. This can often lead to delay in diagnosis as patients see dentists and doctors who consider more common alternatives first.

Table 1 Common conditions that are usually easy to distinguish from Trigeminal Neuralgia

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Important features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dental infection or cracked tooth</td>
<td>Well localised to tooth; local swelling and erythema; appropriate findings on dental examination</td>
</tr>
<tr>
<td>Temporomandibular joint pain</td>
<td>Often bilateral and may radiate around ear and to neck and temples; jaw opening may be limited and can produce an audible click</td>
</tr>
<tr>
<td>Persistent idiopathic facial pain (previously “atypical facial pain”)9</td>
<td>Often bilateral and may extend out of trigeminal territory; pain often continuous, mild to moderate in severity, and aching or throbbing in character</td>
</tr>
<tr>
<td>Migraine</td>
<td>Often preceded by aura; severe unilateral headache often associated with nausea, photophobia, phonophobia, and neck stiffness</td>
</tr>
<tr>
<td>Temporal arteritis</td>
<td>Common in elderly people; temporal pain should be constant and often associated with jaw claudication, fever, and weight loss; temporal arteries may be firm, tender, and non-pulsatile on examination</td>
</tr>
</tbody>
</table>

The treatment of trigeminal neuralgia may be medical or surgical14. The medical therapy is the first choice, resorting to the functional neurosurgery only in cases where clinical therapy proves ineffective15.

At first, carbamazepine and oxcarbazepin drugs must be administered at lower doses, but if necessary, doses may be increased gradually14 as we practiced in our case. Among the surgical procedures most widely used are neurovascular decompression as the primary ablative technique, the radiofrequency rhizotomy, balloon compression and glycerol rhizotomy and radiosurgery16, only 25% of patients present with TN total pain control only with the use of drugs over time17. The drugs most commonly used are: local anesthetics, neuropeptides, muscle relaxants, and anticonvulsants. A summary of results of clinical trials / controlled clinical trials of drug treatment of Trigeminal Neuralgia shows the practice of managing trigeminal neuralgia18.

Surgical treatment is based on the assumption that the cause is of peripheral origin, such as trigeminal nerve damage in a blood vessel, by a tumor or an inflammatory lesion19. In recent years, the two most common procedures used were: a differential percutaneous electrocoagulation of the trigeminal nerve and trigeminal vascular decompression and also with radiofrequency thermocoagulation of the Gasser ganglion an effective method, widely used in patients over 50 years20.
Table 2: Summary of results of clinical trials / controlled clinical trials of drug treatment of Trigeminal Neuralgia*

<table>
<thead>
<tr>
<th>Study</th>
<th>Drugs used</th>
<th>Total no of patients</th>
<th>Total no of patients benefited (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomson 1981</td>
<td>CBZ</td>
<td>8</td>
<td>100</td>
</tr>
<tr>
<td>Farago (1987)</td>
<td>CBZ analogues:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(i) Dihydromonohydroxy</td>
<td>13</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>(ii) Dihydromonooxy</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Liebel (2001)</td>
<td>Oxcarbazepine and CBZ</td>
<td>48</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>(oxcarbazepine)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CBZ</td>
<td>95 (CBZ)</td>
<td></td>
</tr>
<tr>
<td>Zakrzewska et al (2002)</td>
<td>Oxcarbazepine</td>
<td>15</td>
<td>100 Benefited initially</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>80 required surgery</td>
</tr>
<tr>
<td>Lindstrom (1987)</td>
<td>Tocainide and CBZ</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>Lechin et al (1989)</td>
<td>Pimozide and CBZ</td>
<td>48</td>
<td>100 (pimozide)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>56 (CBZ)</td>
</tr>
<tr>
<td>Vilming (1986)</td>
<td>Tizanidine</td>
<td>6</td>
<td>Effects of tizanidine Inferior to CBZ</td>
</tr>
<tr>
<td></td>
<td>CBZ</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Merren (1998)</td>
<td>Gabapentin</td>
<td>60</td>
<td>65</td>
</tr>
<tr>
<td>Fromm (1984)</td>
<td>Baclofen</td>
<td>60</td>
<td>30</td>
</tr>
<tr>
<td>Parmar (1989)</td>
<td>Baclofen</td>
<td>20</td>
<td>65</td>
</tr>
<tr>
<td>From et al (1987)</td>
<td>L-Baclofen and racemic baclofen</td>
<td>9</td>
<td>66.6</td>
</tr>
</tbody>
</table>

Abbreviation: CBZ, carbamazepine.

The decompression technique that is considered to promote relief for a longer time, with control of pain by more than 70% of patients over 10 years. The decompression is indicated in young individuals who want to preserve the facial sensitivity, when there is suspected lesion towards trigeminal neuralgia or when this is combined with other facial neuralgia or hemifacial spasm.

References